Hepatitis C - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：722頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
Hepatitis C - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Hepatitis C - Pipeline Review, H1 2014’, provides an overview of the Hepatitis C’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hepatitis C
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatitis C and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatitis C pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatitis C
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Hepatitis C - Pipeline Review, H1 2014’, provides an overview of the Hepatitis C’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hepatitis C
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatitis C and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatitis C pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatitis C
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 7
Hepatitis C Overview 8
Therapeutics Development 9
Hepatitis C - Therapeutics under Development by Companies 11
Hepatitis C - Therapeutics under Investigation by Universities/Institutes 22
Hepatitis C - Pipeline Products Glance 25
Hepatitis C - Products under Development by Companies 29
Hepatitis C - Products under Investigation by Universities/Institutes 46
Hepatitis C - Companies Involved in Therapeutics Development 48
Hepatitis C - Therapeutics Assessment 178
Drug Profiles 198
Hepatitis C - Recent Pipeline Updates 583
Hepatitis C - Dormant Projects 671
Hepatitis C - Discontinued Products 675
Hepatitis C - Product Development Milestones 677
Appendix 690
List of Tables
Number of Products under Development for Hepatitis C, H1 2014 40
Number of Products under Development for Hepatitis C - Comparative Analysis, H1 2014 41
Number of Products under Development by Companies, H1 2014 43
Number of Products under Development by Companies, H1 2014 (Contd..1) 44
Number of Products under Development by Companies, H1 2014 (Contd..2) 45
Number of Products under Development by Companies, H1 2014 (Contd..3) 46
Number of Products under Development by Companies, H1 2014 (Contd..4) 47
Number of Products under Development by Companies, H1 2014 (Contd..5) 48
Number of Products under Development by Companies, H1 2014 (Contd..6) 49
Number of Products under Development by Companies, H1 2014 (Contd..7) 50
Number of Products under Development by Companies, H1 2014 (Contd..8) 51
Number of Products under Development by Companies, H1 2014 (Contd..9) 52
Number of Products under Investigation by Universities/Institutes, H1 2014 54
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 55
Comparative Analysis by Late Stage Development, H1 2014 56
Comparative Analysis by Clinical Stage Development, H1 2014 57
Comparative Analysis by Early Stage Development, H1 2014 58
Comparative Analysis by Unknown Stage Development, H1 2014 59
Products under Development by Companies, H1 2014 60
Products under Development by Companies, H1 2014 (Contd..1) 61
Products under Development by Companies, H1 2014 (Contd..2) 62
Products under Development by Companies, H1 2014 (Contd..3) 63
Products under Development by Companies, H1 2014 (Contd..4) 64
Products under Development by Companies, H1 2014 (Contd..5) 65
Products under Development by Companies, H1 2014 (Contd..6) 66
Products under Development by Companies, H1 2014 (Contd..7) 67
Products under Development by Companies, H1 2014 (Contd..8) 68
Products under Development by Companies, H1 2014 (Contd..9) 69
Products under Development by Companies, H1 2014 (Contd..10) 70
Products under Development by Companies, H1 2014 (Contd..11) 71
Products under Development by Companies, H1 2014 (Contd..12) 72
Products under Development by Companies, H1 2014 (Contd..13) 73
Products under Development by Companies, H1 2014 (Contd..14) 74
Products under Development by Companies, H1 2014 (Contd..15) 75
Products under Development by Companies, H1 2014 (Contd..16) 76
Products under Investigation by Universities/Institutes, H1 2014 77
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 78
Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H1 2014 79
Hepatitis C - Pipeline by Johnson & Johnson, H1 2014 80
Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H1 2014 81
Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 82
Hepatitis C - Pipeline by United Therapeutics Corporation, H1 2014 83
Hepatitis C - Pipeline by GlaxoSmithKline plc, H1 2014 84
Hepatitis C - Pipeline by Tekmira Pharmaceuticals Corp., H1 2014 85
Hepatitis C - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 86
Hepatitis C - Pipeline by Idenix Pharmaceuticals, Inc., H1 2014 87
Hepatitis C - Pipeline by Gilead Sciences, Inc., H1 2014 88
Hepatitis C - Pipeline by Biotest AG, H1 2014 89
Hepatitis C - Pipeline by Merck & Co., Inc., H1 2014 90
Hepatitis C - Pipeline by Lentigen Corporation, H1 2014 91
Hepatitis C - Pipeline by BioLineRx, Ltd., H1 2014 92
Hepatitis C - Pipeline by Biotron Limited, H1 2014 93
Hepatitis C - Pipeline by Novartis AG, H1 2014 94
Hepatitis C - Pipeline by Achillion Pharmaceuticals, Inc., H1 2014 95
Hepatitis C - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 96
Hepatitis C - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 97
Hepatitis C - Pipeline by Pfizer Inc., H1 2014 98
Hepatitis C - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 99
Hepatitis C - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 100
Hepatitis C - Pipeline by Genmab A/S, H1 2014 101
Hepatitis C - Pipeline by Koronis Pharma, Inc., H1 2014 102
Hepatitis C - Pipeline by Santaris Pharma A/S, H1 2014 103
Hepatitis C - Pipeline by Tacere Therapeutics, Inc., H1 2014 104
Hepatitis C - Pipeline by Crucell N.V., H1 2014 105
Hepatitis C - Pipeline by Celgene Corporation, H1 2014 106
Hepatitis C - Pipeline by XTL Biopharmaceuticals Ltd., H1 2014 107
Hepatitis C - Pipeline by Hemispherx Biopharma, Inc., H1 2014 108
Hepatitis C - Pipeline by Immtech Pharmaceuticals, Inc., H1 2014 109
Hepatitis C - Pipeline by Immunomedics, Inc., H1 2014 110
Hepatitis C - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 111
Hepatitis C - Pipeline by Medivir AB, H1 2014 112
Hepatitis C - Pipeline by Patrys Limited, H1 2014 113
Hepatitis C - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 114
Hepatitis C - Pipeline by Amarillo Biosciences, Inc., H1 2014 115
Hepatitis C - Pipeline by Flamel Technologies S.A., H1 2014 116
Hepatitis C - Pipeline by Transgene SA, H1 2014 117
Hepatitis C - Pipeline by Xenetic Biosciences plc, H1 2014 118
Hepatitis C - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 119
Hepatitis C - Pipeline by LG Life Sciences, Ltd., H1 2014 120
Hepatitis C - Pipeline by Theravance, Inc., H1 2014 121
Hepatitis C - Pipeline by Summit Corporation plc, H1 2014 122
Hepatitis C - Pipeline by Phynova Group Ltd, H1 2014 123
Hepatitis C - Pipeline by Microbio Co., Ltd., H1 2014 124
Hepatitis C - Pipeline by ChronTech Pharma AB, H1 2014 125
Hepatitis C - Pipeline by Raptor Pharmaceuticals Corp., H1 2014 126
Hepatitis C - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 127
Hepatitis C - Pipeline by Digna Biotech, S.L., H1 2014 128
Hepatitis C - Pipeline by Debiopharm International S.A., H1 2014 129
Hepatitis C - Pipeline by StemCells, Inc., H1 2014 130
Hepatitis C - Pipeline by Scynexis, Inc., H1 2014 131
Hepatitis C - Pipeline by Bionor Pharma ASA, H1 2014 132
Hepatitis C - Pipeline by IMGENEX Corporation, H1 2014 133
Hepatitis C - Pipeline by ImmunoBiology Ltd., H1 2014 134
Hepatitis C - Pipeline by Medipol SA, H1 2014 135
Hepatitis C - Pipeline by Altor BioScience Corporation, H1 2014 136
Hepatitis C - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 137
Hepatitis C - Pipeline by PT Bio Farma, H1 2014 138
Hepatitis C - Pipeline by Eiger BioPharmaceuticals, Inc., H1 2014 139
Hepatitis C - Pipeline by AiCuris GmbH & Co. KG, H1 2014 140
Hepatitis C - Pipeline by Okairos AG, H1 2014 141
Hepatitis C - Pipeline by PTC Therapeutics, Inc., H1 2014 142
Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc., H1 2014 143
Hepatitis C - Pipeline by Kineta, Inc., H1 2014 144
Hepatitis C - Pipeline by Presidio Pharmaceuticals, Inc., H1 2014 145
Hepatitis C - Pipeline by Romark Laboratories, L.C., H1 2014 146
Hepatitis C - Pipeline by Chimerix, Inc., H1 2014 147
Hepatitis C - Pipeline by REPLICor Inc., H1 2014 148
Hepatitis C - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 149
Hepatitis C - Pipeline by Immunotope, Inc., H1 2014 150
Hepatitis C - Pipeline by GeneCure LLC, H1 2014 151
Hepatitis C - Pipeline by Microbiotix, Inc., H1 2014 152
Hepatitis C - Pipeline by Bolder Biotechnology, Inc., H1 2014 153
Hepatitis C - Pipeline by Oncolys BioPharma Inc., H1 2014 154
Hepatitis C - Pipeline by Globeimmune, Inc., H1 2014 155
Hepatitis C - Pipeline by Janssen Pharmaceuticals, Inc., H1 2014 156
Hepatitis C - Pipeline by Immunocore Limited, H1 2014 157
Hepatitis C - Pipeline by Enanta Pharmaceuticals, Inc., H1 2014 158
Hepatitis C - Pipeline by Canopus BioPharma Incorporated, H1 2014 159
Hepatitis C - Pipeline by Seek, H1 2014 160
Hepatitis C - Pipeline by Quintessence Biosciences, Inc., H1 2014 161
Hepatitis C - Pipeline by Epiphany Biosciences, Inc., H1 2014 162
Hepatitis C - Pipeline by Alios BioPharma, Inc., H1 2014 163
Hepatitis C - Pipeline by CureTech Ltd., H1 2014 164
Hepatitis C - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2014 165
Hepatitis C - Pipeline by VBI Vaccines, H1 2014 166
Hepatitis C - Pipeline by PharmaEssentia Corporation, H1 2014 167
Hepatitis C - Pipeline by NasVax Ltd., H1 2014 168
Hepatitis C - Pipeline by iQur Ltd., H1 2014 169
Hepatitis C - Pipeline by Regulus Therapeutics Inc., H1 2014 170
Hepatitis C - Pipeline by Rodos BioTarget GmbH, H1 2014 171
Hepatitis C - Pipeline by AIMM Therapeutics B.V., H1 2014 172
Hepatitis C - Pipeline by Sorrento Therapeutics, Inc., H1 2014 173
Hepatitis C - Pipeline by Cocrystal Discovery, Inc., H1 2014 174
Hepatitis C - Pipeline by Profectus BioSciences, Inc., H1 2014 175
Hepatitis C - Pipeline by 3-V Biosciences, Inc., H1 2014 176
Hepatitis C - Pipeline by DiscoveryBiomed, Inc., H1 2014 177
Hepatitis C - Pipeline by Ascendis Pharma A/S, H1 2014 178
Hepatitis C - Pipeline by ViroLogik GmbH, H1 2014 179
Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H1 2014 180
Hepatitis C - Pipeline by B&C Biopharm, H1 2014 181
Hepatitis C - Pipeline by Pfenex Inc., H1 2014 182
Hepatitis C - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014 183
Hepatitis C - Pipeline by Therapure Biopharma Inc., H1 2014 184
Hepatitis C - Pipeline by NAL Pharmaceuticals Ltd., H1 2014 185
Hepatitis C - Pipeline by DEKK-TEC, Inc., H1 2014 186
Hepatitis C - Pipeline by iTherX, Inc., H1 2014 187
Hepatitis C - Pipeline by AUS Bio Limited, H1 2014 188
Hepatitis C - Pipeline by SomaGenics Inc., H1 2014 189
Hepatitis C - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2014 190
Hepatitis C - Pipeline by Nexigen GmbH, H1 2014 191
Hepatitis C - Pipeline by Sumagen Co., Ltd., H1 2014 192
Hepatitis C - Pipeline by Delpor, Inc., H1 2014 193
Hepatitis C - Pipeline by Hepacyl Therapeutics, SL, H1 2014 194
Hepatitis C - Pipeline by Rottapharm|Madaus, H1 2014 195
Hepatitis C - Pipeline by Xiamen Amoytop Biotech Co., Ltd., H1 2014 196
Hepatitis C - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 197
Hepatitis C - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 198
Hepatitis C - Pipeline by American Gene Technologies International Inc., H1 2014 199
Hepatitis C - Pipeline by GinkgoPharma Co. Ltd., H1 2014 200
Hepatitis C - Pipeline by Vaxeal Holding SA, H1 2014 201
Hepatitis C - Pipeline by Conkwest, Inc., H1 2014 202
Hepatitis C - Pipeline by ARA Healthcare Pvt. Ltd., H1 2014 203
Hepatitis C - Pipeline by Biota Pharmaceuticals, Inc., H1 2014 204
Hepatitis C - Pipeline by Biocad, H1 2014 205
Hepatitis C - Pipeline by Humabs BioMed SA, H1 2014 206
Hepatitis C - Pipeline by AbbVie Inc., H1 2014 207
Hepatitis C - Pipeline by Hependo Sp. z o. o. (Ltd), H1 2014 208
Assessment by Monotherapy Products, H1 2014 209
Assessment by Combination Products, H1 2014 210
Number of Products by Stage and Target, H1 2014 213
Number of Products by Stage and Mechanism of Action, H1 2014 219
Number of Products by Stage and Route of Administration, H1 2014 225
Number of Products by Stage and Molecule Type, H1 2014 228
Hepatitis C Therapeutics - Recent Pipeline Updates, H1 2014 614
Hepatitis C - Dormant Projects, H1 2014 702
Hepatitis C - Discontinued Products, H1 2014 706
List of Figures
Number of Products under Development for Hepatitis C, H1 2014 40
Number of Products under Development for Hepatitis C - Comparative Analysis, H1 2014 41
Number of Products under Development by Companies, H1 2014 42
Number of Products under Investigation by Universities/Institutes, H1 2014 53
Comparative Analysis by Late Stage Development, H1 2014 56
Comparative Analysis by Clinical Stage Development, H1 2014 57
Comparative Analysis by Early Stage Products, H1 2014 58
Assessment by Monotherapy Products, H1 2014 209
Assessment by Combination Products, H1 2014 210
Number of Products by Top 10 Target, H1 2014 211
Number of Products by Stage and Top 10 Target, H1 2014 212
Number of Products by Top 10 Mechanism of Action, H1 2014 217
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 218
Number of Products by Top 10 Route of Administration, H1 2014 223
Number of Products by Stage and Top 10 Route of Administration, H1 2014 224
Number of Products by Top 10 Molecule Type, H1 2014 226
Number of Products by Stage and Top 10 Molecule Type, H1 2014 227
Table of Contents 2
Introduction 7
Hepatitis C Overview 8
Therapeutics Development 9
Hepatitis C - Therapeutics under Development by Companies 11
Hepatitis C - Therapeutics under Investigation by Universities/Institutes 22
Hepatitis C - Pipeline Products Glance 25
Hepatitis C - Products under Development by Companies 29
Hepatitis C - Products under Investigation by Universities/Institutes 46
Hepatitis C - Companies Involved in Therapeutics Development 48
Hepatitis C - Therapeutics Assessment 178
Drug Profiles 198
Hepatitis C - Recent Pipeline Updates 583
Hepatitis C - Dormant Projects 671
Hepatitis C - Discontinued Products 675
Hepatitis C - Product Development Milestones 677
Appendix 690
List of Tables
Number of Products under Development for Hepatitis C, H1 2014 40
Number of Products under Development for Hepatitis C - Comparative Analysis, H1 2014 41
Number of Products under Development by Companies, H1 2014 43
Number of Products under Development by Companies, H1 2014 (Contd..1) 44
Number of Products under Development by Companies, H1 2014 (Contd..2) 45
Number of Products under Development by Companies, H1 2014 (Contd..3) 46
Number of Products under Development by Companies, H1 2014 (Contd..4) 47
Number of Products under Development by Companies, H1 2014 (Contd..5) 48
Number of Products under Development by Companies, H1 2014 (Contd..6) 49
Number of Products under Development by Companies, H1 2014 (Contd..7) 50
Number of Products under Development by Companies, H1 2014 (Contd..8) 51
Number of Products under Development by Companies, H1 2014 (Contd..9) 52
Number of Products under Investigation by Universities/Institutes, H1 2014 54
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 55
Comparative Analysis by Late Stage Development, H1 2014 56
Comparative Analysis by Clinical Stage Development, H1 2014 57
Comparative Analysis by Early Stage Development, H1 2014 58
Comparative Analysis by Unknown Stage Development, H1 2014 59
Products under Development by Companies, H1 2014 60
Products under Development by Companies, H1 2014 (Contd..1) 61
Products under Development by Companies, H1 2014 (Contd..2) 62
Products under Development by Companies, H1 2014 (Contd..3) 63
Products under Development by Companies, H1 2014 (Contd..4) 64
Products under Development by Companies, H1 2014 (Contd..5) 65
Products under Development by Companies, H1 2014 (Contd..6) 66
Products under Development by Companies, H1 2014 (Contd..7) 67
Products under Development by Companies, H1 2014 (Contd..8) 68
Products under Development by Companies, H1 2014 (Contd..9) 69
Products under Development by Companies, H1 2014 (Contd..10) 70
Products under Development by Companies, H1 2014 (Contd..11) 71
Products under Development by Companies, H1 2014 (Contd..12) 72
Products under Development by Companies, H1 2014 (Contd..13) 73
Products under Development by Companies, H1 2014 (Contd..14) 74
Products under Development by Companies, H1 2014 (Contd..15) 75
Products under Development by Companies, H1 2014 (Contd..16) 76
Products under Investigation by Universities/Institutes, H1 2014 77
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 78
Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H1 2014 79
Hepatitis C - Pipeline by Johnson & Johnson, H1 2014 80
Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H1 2014 81
Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 82
Hepatitis C - Pipeline by United Therapeutics Corporation, H1 2014 83
Hepatitis C - Pipeline by GlaxoSmithKline plc, H1 2014 84
Hepatitis C - Pipeline by Tekmira Pharmaceuticals Corp., H1 2014 85
Hepatitis C - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 86
Hepatitis C - Pipeline by Idenix Pharmaceuticals, Inc., H1 2014 87
Hepatitis C - Pipeline by Gilead Sciences, Inc., H1 2014 88
Hepatitis C - Pipeline by Biotest AG, H1 2014 89
Hepatitis C - Pipeline by Merck & Co., Inc., H1 2014 90
Hepatitis C - Pipeline by Lentigen Corporation, H1 2014 91
Hepatitis C - Pipeline by BioLineRx, Ltd., H1 2014 92
Hepatitis C - Pipeline by Biotron Limited, H1 2014 93
Hepatitis C - Pipeline by Novartis AG, H1 2014 94
Hepatitis C - Pipeline by Achillion Pharmaceuticals, Inc., H1 2014 95
Hepatitis C - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 96
Hepatitis C - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 97
Hepatitis C - Pipeline by Pfizer Inc., H1 2014 98
Hepatitis C - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 99
Hepatitis C - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 100
Hepatitis C - Pipeline by Genmab A/S, H1 2014 101
Hepatitis C - Pipeline by Koronis Pharma, Inc., H1 2014 102
Hepatitis C - Pipeline by Santaris Pharma A/S, H1 2014 103
Hepatitis C - Pipeline by Tacere Therapeutics, Inc., H1 2014 104
Hepatitis C - Pipeline by Crucell N.V., H1 2014 105
Hepatitis C - Pipeline by Celgene Corporation, H1 2014 106
Hepatitis C - Pipeline by XTL Biopharmaceuticals Ltd., H1 2014 107
Hepatitis C - Pipeline by Hemispherx Biopharma, Inc., H1 2014 108
Hepatitis C - Pipeline by Immtech Pharmaceuticals, Inc., H1 2014 109
Hepatitis C - Pipeline by Immunomedics, Inc., H1 2014 110
Hepatitis C - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 111
Hepatitis C - Pipeline by Medivir AB, H1 2014 112
Hepatitis C - Pipeline by Patrys Limited, H1 2014 113
Hepatitis C - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 114
Hepatitis C - Pipeline by Amarillo Biosciences, Inc., H1 2014 115
Hepatitis C - Pipeline by Flamel Technologies S.A., H1 2014 116
Hepatitis C - Pipeline by Transgene SA, H1 2014 117
Hepatitis C - Pipeline by Xenetic Biosciences plc, H1 2014 118
Hepatitis C - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 119
Hepatitis C - Pipeline by LG Life Sciences, Ltd., H1 2014 120
Hepatitis C - Pipeline by Theravance, Inc., H1 2014 121
Hepatitis C - Pipeline by Summit Corporation plc, H1 2014 122
Hepatitis C - Pipeline by Phynova Group Ltd, H1 2014 123
Hepatitis C - Pipeline by Microbio Co., Ltd., H1 2014 124
Hepatitis C - Pipeline by ChronTech Pharma AB, H1 2014 125
Hepatitis C - Pipeline by Raptor Pharmaceuticals Corp., H1 2014 126
Hepatitis C - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 127
Hepatitis C - Pipeline by Digna Biotech, S.L., H1 2014 128
Hepatitis C - Pipeline by Debiopharm International S.A., H1 2014 129
Hepatitis C - Pipeline by StemCells, Inc., H1 2014 130
Hepatitis C - Pipeline by Scynexis, Inc., H1 2014 131
Hepatitis C - Pipeline by Bionor Pharma ASA, H1 2014 132
Hepatitis C - Pipeline by IMGENEX Corporation, H1 2014 133
Hepatitis C - Pipeline by ImmunoBiology Ltd., H1 2014 134
Hepatitis C - Pipeline by Medipol SA, H1 2014 135
Hepatitis C - Pipeline by Altor BioScience Corporation, H1 2014 136
Hepatitis C - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 137
Hepatitis C - Pipeline by PT Bio Farma, H1 2014 138
Hepatitis C - Pipeline by Eiger BioPharmaceuticals, Inc., H1 2014 139
Hepatitis C - Pipeline by AiCuris GmbH & Co. KG, H1 2014 140
Hepatitis C - Pipeline by Okairos AG, H1 2014 141
Hepatitis C - Pipeline by PTC Therapeutics, Inc., H1 2014 142
Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc., H1 2014 143
Hepatitis C - Pipeline by Kineta, Inc., H1 2014 144
Hepatitis C - Pipeline by Presidio Pharmaceuticals, Inc., H1 2014 145
Hepatitis C - Pipeline by Romark Laboratories, L.C., H1 2014 146
Hepatitis C - Pipeline by Chimerix, Inc., H1 2014 147
Hepatitis C - Pipeline by REPLICor Inc., H1 2014 148
Hepatitis C - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 149
Hepatitis C - Pipeline by Immunotope, Inc., H1 2014 150
Hepatitis C - Pipeline by GeneCure LLC, H1 2014 151
Hepatitis C - Pipeline by Microbiotix, Inc., H1 2014 152
Hepatitis C - Pipeline by Bolder Biotechnology, Inc., H1 2014 153
Hepatitis C - Pipeline by Oncolys BioPharma Inc., H1 2014 154
Hepatitis C - Pipeline by Globeimmune, Inc., H1 2014 155
Hepatitis C - Pipeline by Janssen Pharmaceuticals, Inc., H1 2014 156
Hepatitis C - Pipeline by Immunocore Limited, H1 2014 157
Hepatitis C - Pipeline by Enanta Pharmaceuticals, Inc., H1 2014 158
Hepatitis C - Pipeline by Canopus BioPharma Incorporated, H1 2014 159
Hepatitis C - Pipeline by Seek, H1 2014 160
Hepatitis C - Pipeline by Quintessence Biosciences, Inc., H1 2014 161
Hepatitis C - Pipeline by Epiphany Biosciences, Inc., H1 2014 162
Hepatitis C - Pipeline by Alios BioPharma, Inc., H1 2014 163
Hepatitis C - Pipeline by CureTech Ltd., H1 2014 164
Hepatitis C - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2014 165
Hepatitis C - Pipeline by VBI Vaccines, H1 2014 166
Hepatitis C - Pipeline by PharmaEssentia Corporation, H1 2014 167
Hepatitis C - Pipeline by NasVax Ltd., H1 2014 168
Hepatitis C - Pipeline by iQur Ltd., H1 2014 169
Hepatitis C - Pipeline by Regulus Therapeutics Inc., H1 2014 170
Hepatitis C - Pipeline by Rodos BioTarget GmbH, H1 2014 171
Hepatitis C - Pipeline by AIMM Therapeutics B.V., H1 2014 172
Hepatitis C - Pipeline by Sorrento Therapeutics, Inc., H1 2014 173
Hepatitis C - Pipeline by Cocrystal Discovery, Inc., H1 2014 174
Hepatitis C - Pipeline by Profectus BioSciences, Inc., H1 2014 175
Hepatitis C - Pipeline by 3-V Biosciences, Inc., H1 2014 176
Hepatitis C - Pipeline by DiscoveryBiomed, Inc., H1 2014 177
Hepatitis C - Pipeline by Ascendis Pharma A/S, H1 2014 178
Hepatitis C - Pipeline by ViroLogik GmbH, H1 2014 179
Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H1 2014 180
Hepatitis C - Pipeline by B&C Biopharm, H1 2014 181
Hepatitis C - Pipeline by Pfenex Inc., H1 2014 182
Hepatitis C - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014 183
Hepatitis C - Pipeline by Therapure Biopharma Inc., H1 2014 184
Hepatitis C - Pipeline by NAL Pharmaceuticals Ltd., H1 2014 185
Hepatitis C - Pipeline by DEKK-TEC, Inc., H1 2014 186
Hepatitis C - Pipeline by iTherX, Inc., H1 2014 187
Hepatitis C - Pipeline by AUS Bio Limited, H1 2014 188
Hepatitis C - Pipeline by SomaGenics Inc., H1 2014 189
Hepatitis C - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2014 190
Hepatitis C - Pipeline by Nexigen GmbH, H1 2014 191
Hepatitis C - Pipeline by Sumagen Co., Ltd., H1 2014 192
Hepatitis C - Pipeline by Delpor, Inc., H1 2014 193
Hepatitis C - Pipeline by Hepacyl Therapeutics, SL, H1 2014 194
Hepatitis C - Pipeline by Rottapharm|Madaus, H1 2014 195
Hepatitis C - Pipeline by Xiamen Amoytop Biotech Co., Ltd., H1 2014 196
Hepatitis C - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 197
Hepatitis C - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 198
Hepatitis C - Pipeline by American Gene Technologies International Inc., H1 2014 199
Hepatitis C - Pipeline by GinkgoPharma Co. Ltd., H1 2014 200
Hepatitis C - Pipeline by Vaxeal Holding SA, H1 2014 201
Hepatitis C - Pipeline by Conkwest, Inc., H1 2014 202
Hepatitis C - Pipeline by ARA Healthcare Pvt. Ltd., H1 2014 203
Hepatitis C - Pipeline by Biota Pharmaceuticals, Inc., H1 2014 204
Hepatitis C - Pipeline by Biocad, H1 2014 205
Hepatitis C - Pipeline by Humabs BioMed SA, H1 2014 206
Hepatitis C - Pipeline by AbbVie Inc., H1 2014 207
Hepatitis C - Pipeline by Hependo Sp. z o. o. (Ltd), H1 2014 208
Assessment by Monotherapy Products, H1 2014 209
Assessment by Combination Products, H1 2014 210
Number of Products by Stage and Target, H1 2014 213
Number of Products by Stage and Mechanism of Action, H1 2014 219
Number of Products by Stage and Route of Administration, H1 2014 225
Number of Products by Stage and Molecule Type, H1 2014 228
Hepatitis C Therapeutics - Recent Pipeline Updates, H1 2014 614
Hepatitis C - Dormant Projects, H1 2014 702
Hepatitis C - Discontinued Products, H1 2014 706
List of Figures
Number of Products under Development for Hepatitis C, H1 2014 40
Number of Products under Development for Hepatitis C - Comparative Analysis, H1 2014 41
Number of Products under Development by Companies, H1 2014 42
Number of Products under Investigation by Universities/Institutes, H1 2014 53
Comparative Analysis by Late Stage Development, H1 2014 56
Comparative Analysis by Clinical Stage Development, H1 2014 57
Comparative Analysis by Early Stage Products, H1 2014 58
Assessment by Monotherapy Products, H1 2014 209
Assessment by Combination Products, H1 2014 210
Number of Products by Top 10 Target, H1 2014 211
Number of Products by Stage and Top 10 Target, H1 2014 212
Number of Products by Top 10 Mechanism of Action, H1 2014 217
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 218
Number of Products by Top 10 Route of Administration, H1 2014 223
Number of Products by Stage and Top 10 Route of Administration, H1 2014 224
Number of Products by Top 10 Molecule Type, H1 2014 226
Number of Products by Stage and Top 10 Molecule Type, H1 2014 227
